Top Markets
Coin of the day
PharmAust Limited PharmAust Limited

PharmAust Limited

PAA
Rangering i aksjer #26700
Operating internationally, including in Switzerland, Australia, Sweden, and the... Operating internationally, including in Switzerland, Australia, Sweden, and the United States, PharmAust Limited specializes in developing targeted cancer treatments for both human and animal applications. The company also cultivates intellectual property in drug discovery, addressing a range of cancers and neurological conditions. Its primary therapeutic candidate is Monepantel (MPL), a small molecule compound currently undergoing Phase II clinical trials for cancer treatment. Beyond its drug development pipeline, PharmAust provides synthetic and medicinal chemistry products and expert services to the global drug discovery and pharmaceutical sectors. The firm also holds a research agreement with the Walter and Eliza Hall Institute, investigating in vitro the effects of MPL on human T-lymphotrophic virus-1 (HTLV-1) infections. Established in 2000, PharmAust Limited is headquartered in Bentley, Australia.
Aksjekurs
$0.12164306
Sist synkronisert: 2024-11-11
Markedsverdi
$38.53M
Endring (1 dag)
-4.14%
Endring (1 år)
0.00%
Land
AU
Handel PharmAust Limited (PAA)

Kategori

Inntekter for PharmAust Limited (PAA)
Inntekter i Jun 2024 TTM: $572.45K
Ifølge de nyeste økonomiske rapportene til PharmAust Limited er selskapets nåværende inntekter (TTM) $572.45K. I 2023 hadde selskapet inntekter på $1.88M en nedgang sammenlignet med inntektene i 2022, som var $2.33M. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for PharmAust Limited fra 2001 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
2026 (TTM) $572.45K 0.00%
2024 0.00 -100.00%
2023 $1.88M -19.32%
2022 $2.33M 45.33%
2021 $1.60M -27.22%
2020 $2.21M -27.76%
2019 $3.05M 26.47%
2018 $2.41M -5.23%
2017 $2.55M 25.80%
2016 $2.02M 10.90%
2015 $1.83M -0.20%
2014 $1.83M 17.05%
2013 $1.56M -5.48%
2012 $1.65M -0.67%
2011 $1.66M 19.79%
2010 $1.39M -2.17%
2009 $1.42M -47.01%
2008 $2.68M -55.73%
2007 $6.05M 33.53%
2006 $4.53M 85.63%
2005 $2.44M 1,047.74%
2004 $212.83K 366.98%
2003 $45.58K -88.07%
2002 $381.98K 0.00%
2001 0.00 0.00%
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$12.62B 2,205,224.96%
US
$6.02B 1,051,752.00%
NL
$15.70B 2,741,683.32%
AU
$2.23B 389,106.85%
US
- -
CH